Historical ew News Stories

Edwards Lifesciences' Stock Performance Amidst Analyst Upgrades and Earnings Beat

Edwards Lifesciences' stock rises following analyst upgrades and strong Q2 earnings.

Edwards Lifesciences' Stock Decline Amid Margin Pressures and Cautious 2026 Outlook

Edwards Lifesciences' stock declines due to margin pressures and cautious 2026 outlook.

Edwards Lifesciences' SAPIEN M3 Approval and Financial Outlook Impact Stock Performance

Edwards Lifesciences' SAPIEN M3 approval and financial outlook impact stock performance.

Edwards Lifesciences' Stock Performance Amidst Medicare's Health Tech Spending Test

Analyzing EW's stock in light of Medicare's new health tech initiative.

Edwards Lifesciences: 10-Year Resilia Data Lift Up

Edwards Lifesciences (EW) gained momentum this week after releasing 10-year durability data for its Resilia tissue, filing a Form 10‑Q reflecting strong Q1 performance, and announcing a CFO transition—alongside mixed insider and institutional trading activity. These concrete developments strengthen product credibility and clarify near-term leadership continuity.

Edwards Lifesciences: Q1 Beat, 10-Year Valve Data

Edwards Lifesciences reported a strong Q1 with $1.65B revenue, raised full-year guidance, and released 10-year COMMENCE trial data supporting Resilia tissue durability. A new CFO appointment and positive analyst reactions underscore growing investor confidence in the company’s TAVR and transcatheter valve franchises.

Edwards Lifesciences Q1 Beat, Guidance Lift EW

Edwards Lifesciences reported a stronger-than-expected Q1 with $1.65B revenue, raised full-year guidance, and completed a $500M accelerated buyback—boosting sentiment even as valuation remains rich and institutional trimming surfaces.

Edwards Lifesciences: CMS NCA & EU Probe Update

Key regulatory moves — EU antitrust probe closed and CMS launched its NCA for asymptomatic TAVR — plus insider buys and FDA RWE shifts that materially affect Edwards Lifesciences (EW).

Edwards' Lifesciences: Recall, R&D & Insider Buys.

Edwards Lifesciences faced a voluntary recall of its Sapphire TAVR valve this week, introducing short-term sales pressure amid a company reorganization. At the same time, the firm's proxy confirms continued heavy R&D investment and strong regulatory progress, while recent insider purchases signal management confidence. Investors should weigh near-term operational risks against long-term innovation momentum.

Edwards Lifesciences Gets Goldman Buy, $89 Target

Goldman Sachs reiterated a Buy rating and set an $89 target on Edwards Lifesciences (EW), citing TAVR strength and TMTT growth opportunities. Technical analysis this week also showed bullish momentum with short-term support near $83–$84 and resistance around $87–$89 — offering defined risk-reward for investors.

Edwards Lifesciences: Q4 Beat, EU Win; Shares Surge

Edwards Lifesciences (EW) saw a notable stock uptick after a stronger-than-expected Q4 revenue print, lifted guidance for 2026, and resolved an EU antitrust probe by removing its anti-copycat policy. Key drivers: robust TAVR performance, rapid TMTT growth, FDA approval of SAPIEN M3, and disciplined capital returns.

Edwards Lifesciences Gains After Q4 Results Rally!

Edwards Lifesciences (EW) climbed after Q4 results showed revenue slightly above estimates despite an EPS miss. Elevated trading volume, a premium valuation, and upbeat guidance underpin analyst optimism and investor interest in this S&P 500 medtech name.

Edwards Lifesciences: Q4 Beat Sparks Volatility

Edwards Lifesciences reported mixed Q4 results with strong revenue growth driven by TAVR and TMTT products, an EPS miss, and a bullish 2026 outlook. The stock showed sharp post-earnings swings as investors weighed near-term investment plans against long-term growth guidance. Key drivers to monitor include TAVR reimbursement progress, execution on TMTT expansion, and trading volume signaling institutional positioning.

Edwards Lifesciences: Volume Spike Drives Pullback.

Edwards Lifesciences (EW) experienced elevated trading volume and several days of share-price decline in early February 2026, underperforming peers despite solid fundamentals and recent product approvals. Key drivers include heightened investor rebalancing, the commercial ramp of SAPIEN M3, and upcoming clinical data and guidance milestones.